



二重特異性抗体Ex3シリーズ

セツキシマブよりも100倍以上高い抗腫瘍活性を有することをin vivoで確認済み


① Summary



② anti-tumor effect of humanized Ex3 (in vivo)




③ high activation of Ex3




④ Effect of IgG type Ex3 & LH type Ex3 (in vitro)

human bile duct carcinoma (TFK-1) : activated T cell = 1 : 5



⑤ Effect of amino acid mutant of Ex3 (in vitro)



⑥ comparison of anti-tumor effect

1. cetuximab (25µg/kg) < Ex3 (0.1µg/kg)
2. Ex3 < fc fused Ex3
3. HL type Ex3 < LH type Ex3
4. Ex3 (HL) < fc fused Ex3 (HL) < Ex3 (LH) < fc fused Ex3 (LH)
5. amino acid mutant of Ex3 series has higher anti-tumor effect than original Ex3 series

特許データシート(いずれも欧米出願あり)
特許番号: 特許第3803790号, 特許第5082104号,
特許第5725508号, 特許第5818003号
発明者: 熊谷泉、中西猛、浅野竜太郎、梅津光央ら

連絡先

株式会社 東北テクノアーチ
TEL 022-222-3049 FAX 022-222-3419
問い合わせは[こちら](#)からお願いします。